Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
Smith JW 2nd, Vukelja S, Rabe A, Wentworth-Hartung N, Koutrelakos N, Shao SH, Whittaker T, Wang Y, Asmar L, McDowell DO, Mukhopadhyay P, O'Shaughnessy J. Smith JW 2nd, et al. Among authors: mukhopadhyay p. Breast Cancer Res Treat. 2013 Nov;142(2):381-8. doi: 10.1007/s10549-013-2742-4. Epub 2013 Oct 29. Breast Cancer Res Treat. 2013. PMID: 24166282 Clinical Trial.
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Hortobagyi GN, et al. Among authors: mukhopadhyay p. Breast Cancer Res Treat. 2010 Jul;122(2):409-18. doi: 10.1007/s10549-010-0901-4. Epub 2010 May 8. Breast Cancer Res Treat. 2010. PMID: 20454927 Clinical Trial.
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
Valero V, Vrdoljak E, Xu B, Thomas E, Gómez H, Manikhas A, Medina C, Li RK, Ro J, Bosserman L, Vahdat L, Mukhopadhyay P, Opatt D, Sparano JA. Valero V, et al. Among authors: mukhopadhyay p. Clin Breast Cancer. 2012 Aug;12(4):240-6. doi: 10.1016/j.clbc.2012.03.013. Epub 2012 Jun 2. Clin Breast Cancer. 2012. PMID: 22658378 Clinical Trial.
A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.
Kim YH, Muro K, Yasui H, Chen JS, Ryu MH, Park SH, Chu KM, Choo SP, Sanchez T, DelaCruz C, Mukhopadhyay P, Lainas I, Li CP. Kim YH, et al. Among authors: mukhopadhyay p. Cancer Chemother Pharmacol. 2012 Oct;70(4):583-90. doi: 10.1007/s00280-012-1943-6. Epub 2012 Aug 12. Cancer Chemother Pharmacol. 2012. PMID: 22886073 Free PMC article. Clinical Trial.
Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ, Schneider CP, Tsai CM, Kim HT, Quoix E, Luft AV, Kaleta R, Mukhopadhyay P, Trifan OC, Whitaker L, Reck M. Edelman MJ, et al. Among authors: mukhopadhyay p. J Clin Oncol. 2013 Jun 1;31(16):1990-6. doi: 10.1200/JCO.2012.45.3282. Epub 2013 Apr 15. J Clin Oncol. 2013. PMID: 23589560 Clinical Trial.
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L. Saura C, et al. Among authors: mukhopadhyay p. Oncologist. 2013;18(7):787-94. doi: 10.1634/theoncologist.2013-0075. Epub 2013 Jul 12. Oncologist. 2013. PMID: 23853246 Free PMC article. Clinical Trial.
635 results